MET and renal cell carcinoma: Liposomes encapsulating a multi-receptor TKI cabozantinib (CBZ) showed higher cytotoxicity than free CBZ and exhibited sustained inhibition of phosphorylation of Met, protein kinase B (AKT), and mitogen-activated protein kinase (MAPK) pathways in renal cell carcinoma (RCC) cells.